Mostrando 10 resultados de: 14
Filtros aplicados
Publisher
Pharmacogenomics(6)
Pharmacogenomics Journal(3)
European Journal of Clinical Pharmacology(1)
Journal of Clinical Psychopharmacology(1)
Journal of Psychopharmacology(1)
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
ArticleAbstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in paPalabras claves:Adverse events, Antipsychotic, pharmacogenetics, RisperidoneAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusDevelopment of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis
ArticleAbstract: Brain-derived neurotrophic factor (BDNF) plays critical role in the growth, differentation and surviPalabras claves:BDNF, Melting curve, Schizophrenia patients, SYBR, Val66Met polymorphismAutores:Adrián LLerena, Dorado P., Guarino E., Sánchez-Romero M.A.Fuentes:scopusCYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
ArticleAbstract: Purpose: Cytochrome P450 2D6 (CYP2D6) genotypes and the dextromethorphan/dextrorphan (DXM/DXT) metabPalabras claves:CYP2D6, dextromethorphan, ECUADOR, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Enrique Terán, Francisco J.López Hernández, Machín E., Natalia HerasFuentes:scopusCYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusAripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Dorado P., López-Torres E., Penãs-Lledó E.M., Salomón J., Vicario F.Fuentes:scopusLosartan hydroxylation phenotype in an Ecuadorian population: Influence of CYP2C9 genetic polymorphism, habits and gender
ArticleAbstract: Aim: To describe for the first time CYP2C9 hydroxylation phenotype with CYP2C9 genotypes in a HispanPalabras claves:CYP2C9 genotype, CYP2C9 hydroxylation, Ecuadorians, Hispanics, LOSARTÁNAutores:Adrián LLerena, Dorado P., Enrique Terán, Leonardo J. Beltrán, Machín E., Penãs-Lledó E.M.Fuentes:scopusLower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards
ArticleAbstract: Interethnic differences in cytochrome P450 polymorphism might be responsible, at least in part, forPalabras claves:CYP2C9, Hispanics, Mexican-Americans, pharmacogenetics, SpaniardsAutores:Adrián LLerena, Dorado P., Jepson R., Licinio J., O'Kirwan F., Wong M.L.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusPharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
ReviewAbstract: Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic polymorphism oPalabras claves:CYP2D6, Cytochrome p450, debrisoquine, PharmacogenomicsAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusQTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
ArticleAbstract: The role of certain drug metabolizing enzymes in cardiotoxicity, such as CYP2D6 for thioridazine, haPalabras claves:9-hydroxy-risperidone, CYP2C9, CYP2D6, QTc, RisperidoneAutores:Adrián LLerena, Berecz R., De La Rubis A., Dorado P.Fuentes:scopus